DOCSLIB.ORG

Common Formulary of Generic Drugs for Medical Store Organisation, CGHS, Dr

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Common Formulary of Generic Drugs for Medical Store Organisation, CGHS, Dr Common Formulary Of Generic Drugs For Medical Store Organisation, CGHS, Dr. R.M.L Hospital, Safdarjung Hospital And Lady Harding Medical College & Kalawati Saran Children Hospital-2011 With VMS Nos (Vocabulary of Medical Stores) Common Formulary Of Generic Drugs For Medical Store Organisation, CGHS, Dr. R.M.L Hospital, Safdarjung Hospital And Lady Harding Medical College & Kalawati Saran Children Hospital With Effect From 23-05-2011 SlNO VMS No Nomenclature Type of Strength Medicine 1. Anaesthetics 1.1 General Anaesthetics and Oxygen 1 G01002 Halothane Inhalation 250ml (Halothane with Inhalation Inhalation vaporizer) 2 G01003 Isoflurane Inhalation Inhalation Inhalation 3 G01004 Ketamine Hydrochloride 10 mg / ml Injection 10 mg / ml 10ml 4 G01005 Ketamine Hydrochloride 10 mg / ml Injection 50mg/ml 10ml 5 G01006 Nitrous Oxide Inhalation Inhalation 6 G01007 Oxygen Inhalation Inhalation Inhalation 7 G01008 Thiopentone Sodium Injection 0.5 g powder 8 G01009 Thiopentone Sodium Injection 1g powder 9 G01024 Sevoflurane Inhalation 250ml Bott Inhalation Inhalation 10 G01025 Propofol Injection 1% 11 G01027 Desflurane 250 ml Inhalation 250 ml 1.2 Local Anaesthetics 12 G01010 Bupivacaine Hydrochloride Injection 0.25% 13 G01011 Bupivacaine Hydrochloride Injection 0.50% 14 G01012 Bupivacaine in Dextrose Injection 0.5% +7.5% 15 G01013 Ethyl Chloride Spray 1% 16 G01014 Lignocaine Hcl Gel 2-5% 17 G01015 Lignocaine Hcl Injection 2% 18 G01016 Lignocaine Hydrochloride and Dextrose Injection 5% +7.5% 19 G01017 Lignocaine Hydrochloride and Adrenaline Injection 1% + Adrenaline Bitartrate 1% + Adrenaline 1:200,000 1:200,000 20 G01018 Lignocaine Hydrochloride and Adrenaline Injection 2% + Adrenaline Bitartrate Injection 2% + Adrenaline 1:200,000 1:200,000 21 G01026 Benzocaine Gel 20% 22 G01030 Xylocaine spray Spray 10% 1.3 Preoperative Medication and Sedation for Short Term Procedures 23 G01019 Atropine Sulphate Injection 0.6 mg / ml 24 G01020 Diazepam Injection 5 mg / ml 25 G01021 Midazolam Injection 1 mg / ml 26 G01022 Midazolam Injection 5mg/ml 27 G01028 Dexmedetomidine Injection 100mg/ml 28 G01029 Glycopyrroolate Injection 0.2 mg/ml 29 G01031 Atropine Sulphate Injection 1 mg/ml 1.4 Postoperative Respiratory Stimulant 30 G01032 Doxapram Hydrochloride Injection 4 mg / ml 2. A n a l g e s i c s , A n t i p y r e t i c s , N o n s t e r o i d a l Anti-inflammatory Medicines, Medicines used to treat Rheumatoid Disorders. 2.1 Non-Opioid Analgesics, Antipyretics and Nonsteroidal Anti-inflammatory Medicines 31 G02002 Diclofenac Sodium Tablet 50 mg 32 G02004 Diclofenac Sodium Injection 25 mg / ml 33 G02005 Ibuprofen Tablet 200 mg 34 G02006 Ibuprofen Tablet 400mg 35 G02007 Paracetamol Injection 150 mg / ml 36 G02008 Paracetamol Syrup 125 mg / 5ml 37 G02009 Paracetamol Tablet 500 mg 38 G02019 Ibupfofen 400mg + Dextropropoxyphene Tablet 400mg + 65mg 65mg 39 G02020 Paracetamol + Dextropropoxyphene Tablet Paracetamol 500mg + Dextropropoxyphene 65mg 40 G02022 Fentanyl Injection 50ug/ml 2ml ampoule 41 G02025 Diclofenac gel Ointment 1%w/v 42 G02028 Lornoxicam Tablet 8mg 43 G02029 Mefenamic acid Tablet Tablet 44 G02031 Nimesulide Tablet 100mg 2.2 Opioid Analgesics 45 G02010 Morphine sulphate Injection 10mg/ml 46 G02011 Morphine sulphate Tablet 10mg 47 G02012 Pentazocine Hydrochloride Tablet 25 mg 48 G02013 Pentazocine Lactate Injection 30 mg / ml 49 G02014 Pethidine Hydrochloride Injection 50 mg / ml 50 G02030 Morphine sulphate Injection 2mg/ml 51 G02032 Tramadol Injection 50 mg/ ml 52 G02034 Sufentanil citrate Injection 50 mcg (0.05 mg) 2.3 Medicines used to treat Gout 53 G02015 Allopurinol Tablet 100 mg 54 G02016 Colchicine Tablet 0.5mg 2.4 Disease Modifying Agents used in Rheumatoid Disorders 55 G02018 Sulfasalazine Tablet 500 mg 56 G02021 Leflunomide Tablet 10mg 57 G02023 Diacerein Tablet 50mg 58 G02024 Diacerein Capsule 50mg 59 G02026 Etoricoxib Tablet 90mg 60 G02027 Leflunomide Tablet 20 mg 3. Anti allergics and Medicines used in Anaphylaxis 61 G03001 Adrenaline Bitartrate Injection 1 mg / ml 62 G03002 Chlorpheniramine Maleate Tablet 4 mg 63 G03003 Dexchlorpheniramine Maleate Syrup 0.5 mg / 5 ml 64 G03004 Dexamethasone Tablet 0.5mg 65 G03005 Dexamethasone Sodium Phosphate Injection 4 mg / ml 66 G03006 Pheniramine Maleate Injection 22.75 mg / ml 67 G03007 Fexofenadine 120mg Tablet Tablet 120mg 68 G03008 Fexofenadine 180mg Tablet Tablet 180mg 69 G03009 Cetrizine Tablet 10mg 70 G03010 Methyl Prednisolone Acetate Injection 500mg 71 G03011 Azelastine HCL Nasal Spray 0.10% 72 G03012 Fluticasone Propionate Nasal spray 100mcg 73 G03013 Cetrizine Syrup 5mg/5ml 74 G03014 Cyproheptadine Tablet 4mg 75 G03015 Fluticasone Propionate Nasal spray 50mcg 76 G03016 Hydroxyzine Hcl Tablet 10mg 77 G03017 Hydroxyzine Hcl Tablet 25mg 78 G03018 Hydroxyzine Hcl Syrup 10mg/5ml 79 G03019 Levocitrizine Hydrochloride Tablet 5mg 80 G03020 Loratadine Tablet 10mg 81 G03021 Pheniramine Maleate Tablet 25 mg 4. Antidotes and Other Substances used in Poisonings 4.1 Nonspecific 92 G04001 Activated Charcoal Powder Powder 83 G04014 Activated Charcoal Tablet Tablet 4.2 Specific 84 G04002 Antisnake Venom Injection Polyvalent Injection 10 ml Solution/ Lyophilyzed Polyvalent Serum Snake Venom Antiserum 85 G04003 Calcium Gluconate Injection 100 mg / ml 86 G04004 Desferrioxamine Mesylate Injection 500mg 87 G04005 Dimercaprol Injection 50 mg / ml 88 G04006 Flumazenil Injection 0.1 mg / ml 89 G04007 Methylthioninium Chloride (Methylene blue) Injection 10 mg / ml 90 G04008 Naloxone Hcl Injection 0.4 mg / ml 91 G04009 Penicillamine Tablet 250 mg 92 G04010 Pralidoxime Chloride(2-PAM) Injection 25 mg/ml 93 G04011 Sodium Nitrite Injection 30 mg / ml 94 G04013 Oral Iron Chelating Agent (Calfer) Tablet 250mg 95 G04015 DEFERASIROX 100/400 100/400 96 G04016 Deferasirox Tablet 250mg 97 G04017 Deferasirox Tablet 500mg 98 G04018 Flumazenil Injection 2mg 99 G04019 Naloxone Hcl 20 mcg /ml 100 G04020 Sodium Thiosulphate Injection 250mg/ml 5. Anticonvulsants/Antiepileptics 101 G05001 Carbamazepine Tablet 100 mg 102 G05002 Carbamazepine Tablet 200mg 103 G05003 Carbamazepine Syrup 100 mg / 5 ml 104 G05004 Magnesium Sulphate Injection 500 mg /ml 105 G05005 Phenobarbitone Tablet 30 mg 106 G05006 Phenobarbitone Tablet 60mg 107 G05007 Phenobarbitone Injection 200 mg / ml 108 G05008 Phenytoin Sodium Tablet 50mg 109 G05009 Phenytoin Sodium Tablet 100 mg 110 G05010 Phenytoin sodium Syrup 125mg/5ml 111 G05011 Phenytoin Sodium Injection 50 mg / ml 112 G05012 Sodium Valproate Tablet 200 mg 113 G05013 Sodium Valproate Tablet 500mg 114 G05014 Sodium Valproate Solution 200 mg / 5 ml 115 G05015 Carbamazepine control release Tablet 400 mg control release 116 G05016 Gabapentin Tablet 300 mg 117 G05017 Leveteracetam Injection 100mg/ml 118 G05018 Leveteracetam Tablet 500mg 119 G05019 Oxacarbamazepine Tablet 150 mg 120 G05020 Oxacarbamazepine Tablet 300mg 121 G05021 Oxacarbamazepine Tablet 250mg 122 G05022 Sodium Valproate Injection 100mg/ml. 123 G05023 Topiramate Tablet 25mg 124 G05024 Zonisamide Tablet 100mg. 6. Antiinfective Medicines 6.1 Anthelminthics 6.1.1 Intestinal Anthelminthics 125 G06001 Albendazole Tablet 400 mg 126 G06002 Albendazole Suspension 200 mg/ 5 ml 127 G06003 Mebendazole Tablet 100 mg 128 G06004 Mebendazole Suspension 100 mg / 5 ml 129 G06007 Pyrantel Pamoate Suspension 250 mg / 5 ml 130 G06226 Ivermectin + Albendazol Tablet Tablet 131 G06227 Levamisole Tablet 55 mg 6.1.2 Antifilarials 132 G06008 Diethylcarbamazine Citrate Tablet 50mg 6.2 Antibacterials 6.2.1 Beta Lactam Medicines 133 G06010 Amoxycillin Suspension 125 mg / 5 ml 134 G06011 Amoxycillin Trihydrate Cap 250 mg 135 G06012 Amoxycillin Trihydrate Cap 500mg 136 G06013 Ampicillin Cap 250mg 137 G06014 Ampicillin Cap 500mg 138 G06015 Ampicillin Suspension 125 mg / 5 ml 139 G06016 Ampicillin Sodium Injection 500 mg 140 G06017 Benzathine Penicillin Injection 6 lac 141 G06018 Benzathine Penicillin Injection 12 lacs 142 G06020 Benzyl Penicillin 5 lacs units Injection Injection 5lac 143 G06021 Benzyl Penicillin 10 lacs units Injection Injection 10 lacs 144 G06022 Cefotaxime Injection 125 mg 145 G06023 Cefotaxime Injection 250 mg 146 G06024 Cefotaxime Injection 500mg 147 G06025 Ceftazidime Injection 250mg 148 G06026 Ceftazidime Injection 1g 149 G06027 Ceftriaxone Sodium Injection 250mg 150 G06028 Ceftriaxone Sodium Injection 1 g 151 G06029 Cefuroxime Sodium Injection 250 mg 152 G06030 Cefuroxime Sodium Injection 750mg 153 G06031 Cloxacillin Sodium Capsule 250mg 154 G06032 Cloxacillin Sodium Capsule 500mg 155 G06033 Cloxacillin Sodium Injection 250mg 156 G06034 Cloxacillin Sodium Liquid 125 mg / 5 ml 157 G06035 Fortified Procaine Penicillin Injection Injection Injection 158 G06155 Cefoperazone + Sulbactum Injection 0.5g + 0.5g 159 G06156 Cefoperazone + Sulbactum Injection 1g. + 1g. 160 G06157 Ampicillin + Cloxacillin Tablet 250mg + 250mg 161 G06158 Ampicillin + Cloxacillin Injection 250mg + 250mg 162 G06159 Amoxycillin + Cloxacillin Tablet 250mg + 250mg 163 G06160 Amoxycillin + Cloxacillin Injection 250mg + 250mg 164 G06161 Ticarcillin + Clavulinic Acid (3G+0.1G) Injection (3G+0.1G) 165 G06162 Ampicillin + Salbactum Injection 1G + 0.5G 166 G06168 Cefuroxine Axetil Tablet 250mg 167 G06169 Cefuroxime Axetil Tablet 500 mg 168 G06170 Cefixime Tablet 200mg 169 G06171 Cefaclor Capsule 500mg 170 G06172 Cefpodoxime Proxetil Tablet 100mg 171 G06173 Cefpodoxime Proxetil Tablet 200mg 172 G06174 Cefadroxine Tablet 500mg 173 G06175 Cefoperazone Injection 500mg 174 G06176 Cefoperazone Injection 1g 175 G06186 Imipenem Hydrochloride Injection 1g 176 G06192 Amoxycillin + Calvulanic
Load more

Recommended publications
  • UNASYN® (Ampicillin Sodium/Sulbactam Sodium)
    NDA 50-608/S-029 Page 3 UNASYN® (ampicillin sodium/sulbactam sodium) PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION To reduce the development of drug-resistant bacteria and maintain the effectiveness of UNASYN® and other antibacterial drugs, UNASYN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION UNASYN is an injectable antibacterial combination consisting of the semisynthetic antibiotic ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium for intravenous and intramuscular administration. Ampicillin sodium is derived from the penicillin nucleus, 6-aminopenicillanic acid. Chemically, it is monosodium (2S, 5R, 6R)-6-[(R)-2-amino-2-phenylacetamido]- 3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate and has a molecular weight of 371.39. Its chemical formula is C16H18N3NaO4S. The structural formula is: COONa O CH3 N CH O 3 NH S NH2 Sulbactam sodium is a derivative of the basic penicillin nucleus. Chemically, sulbactam sodium is sodium penicillinate sulfone; sodium (2S, 5R)-3,3-dimethyl-7-oxo-4-thia­ 1-azabicyclo [3.2.0] heptane-2-carboxylate 4,4-dioxide. Its chemical formula is C8H10NNaO5S with a molecular weight of 255.22. The structural formula is: NDA 50-608/S-029 Page 4 COONa CH3 O N CH3 S O O UNASYN, ampicillin sodium/sulbactam sodium parenteral combination, is available as a white to off-white dry powder for reconstitution. UNASYN dry powder is freely soluble in aqueous diluents to yield pale yellow to yellow solutions containing ampicillin sodium and sulbactam sodium equivalent to 250 mg ampicillin per mL and 125 mg sulbactam per mL.
    [Show full text]
  • Estrogen Metabolism in the Human Estrogen Metabolism in the Human
    ENE PURRE: ESTROGEN METABOLISM IN THE HUMAN ESTROGEN METABOLISM IN THE HUMAN A THESIS BY ENE PURRE SUBMITTED TO THE FACULTY OF GRADUATE STUDIES AND RESEARCH IN PARTIAL FULFILMENT FOR THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE McGILL UNIVERSITY MONTREAL, CANADA. DEPARTMENT OF EXPERIMENTAL MEDICINE AUGUST 1965 TABLE OF CONTENTS Page No. I INTRODUCTION A. Early history and isolation of the e strogens 2 B. Metabolism of the estrogens 4 1. Biogenesis 4 2. Metabolism 6 3. Degradation 14 4. Conjugation 15 c. Altered states of estrogen metabolism 18 Purpose of the Investigation II MATERIALS AND METHODS 25 Materials I Radioactive compounds 25 II Non-radioactive compounds 25 Ill Enzymes 26 IV Reagents 26 Methods I Purification of radioactive steroids 30 II Preparation of non-radioactive standards 31 III Spectophotometric and f1uorimetric readings 31 IV Counting methods 32 V Enzyme assays 33 VI Injections 33 VII Collection of urine 34 VIII Hydrolysis and extraction of urines 34 IX Assay of estrone, estradiol-17 f.:' and estriol 36 X Attempts at separa ting ring 011( keto1s 3 7 XI Assay of ring D..: ketols in the urine 39 XII Recrysta1lization studies 40 ---------------···---- TABLE OF CONTENTS (cont.) Page No._ Ill RESULTS Section I - Studies with control subjects and those with myocardial infarction 41 Section II- A. Recovery of 16~-hydroxyestrone and 16-ketoestradiol-17~ from toluene/ propylene glycol system 50 B. Pre 1 imi nary study on urinary ring De>< ketols 51 c. Urinary ring D<K ke to 1 s in nonnal males 53 D. Studies of the excretion and metabolism of eight estrogen metabolites from urine 59 IV DISCUSSION 71 SUMMARY 87 BIBLIOGRAPHY 89 • LIST OF FIGURES Figure No.
    [Show full text]
  • AUGMENTIN® (Amoxicillin/Clavulanate Potassium) Tablets
    NDA 50-564/S-051 Page 3 AG:AL16 PRESCRIBING INFORMATION AUGMENTIN® (amoxicillin/clavulanate potassium) Tablets To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN (amoxicillin/clavulanate potassium) and other antibacterial drugs, AUGMENTIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION AUGMENTIN is an oral antibacterial combination consisting of the semisynthetic antibiotic amoxicillin and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin is an analog of ampicillin, derived from the basic penicillin nucleus, 6-aminopenicillanic acid. The amoxicillin molecular formula is C16H19N3O5S•3H2O, and the molecular weight is 419.46. Chemically, amoxicillin is (2S,5R,6R)-6-[(R)-(-)-2-Amino-2-(p- hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate and may be represented structurally as: Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus. It is a β-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of β-lactamases by blocking the active sites of these enzymes. Clavulanic acid is particularly active against the clinically important plasmid-mediated β-lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins. The clavulanate potassium molecular formula is C8H8KNO5, and the molecular weight is 237.25. Chemically, clavulanate potassium is potassium (Z)- (2R,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate, and may be represented structurally as: Inactive Ingredients: Colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, and titanium dioxide.
    [Show full text]
  • The Endocrine Function of the Placenta: Interactions Between Trophic Peptides and Hormones
    Placenlal Function and Fetal Nutrition, edited by Frederick C. Battaglia, Nestle Nutrition Workshop Series. Vol. 39. Nestec Ltd.. Vevey/Lippincott-Raven Publishers. Philadelphia. © 1997. The Endocrine Function of the Placenta: Interactions Between Trophic Peptides and Hormones Lise Cedard U. 361 INSERM, Maternite Baudelocque, 121 Boulevard de Port-Royal Paris, France The placenta is classically considered to be a source of hormones that play an important role in the establishment and maintenance of pregnancy. Because of its hemochorial structure, the human placenta produces hormones and easily secretes them into the maternal circulation. They include steroid hormones, such as estrogens and progesterone, and protein hormones, the most important of which are the chori- onic gonadotrophins (hCG), discovered in 1927. During the period from 1960 to 1980, the concept of a fetoplacental unit (1) with a complementary role for the fetus in steroid production offered a new approach to steroid metabolism, and since then new proteins and neuropeptides have been discovered (2,3). However, the lack of innervation of placental tissue highlights the importance of understanding neuroen- docrine regulation of placental physiology. Sophisticated culture methods enabling the study of biologic phenomena occurring during transformation of cytotrophoblast cells into a syncytiotrophoblast (4) have been combined with electron microscopy and histochemistry. Possibilities offered by molecular biology, including in situ hybridization and molecular cloning studies,
    [Show full text]
  • Generic Formulary - 2015 S
    GENERIC FORMULARY - 2015 S. N. Composition Strength Form VMS_code NEW VMS 1. Anaesthetics 1 Atropine 0.6 mg / ml Inj G01019 2 Benzocaine 20% Gel G01026 3 Bupivacaine 25mg/10ml Inj G01010 4 Bupivacaine 50mg/10ml Inj G01011 5 Bupivacaine in Dextrose 5% +7.5% Inj G01012 6 Desflurane 250 ml Inhalation G01027 7 Dexmedetomidine 100mg/ml Inj G01028 8 Diazepam 5 mg/ml Inj G01020 9 Doxapram 4 mg/ml Inj G01032 10 Ethyl Chloride 1% Spray G01013 11 Glycopyrroolate 0.2 mg/ml Inj G01029 12 Halothane Inhalation Inhalation G01002 13 Isoflurane Inhalation Inhalation G01003 14 Ketamine 50mg/ml Inj G01005 15 Ketamine 10 mg / ml Inj G01004 16 Lignocaine and Adrenaline 1% + 1:200,000 Inj G01017 17 Lignocaine and Adrenaline 2% + 1:200,000 Inj G01018 18 Lignocaine and Dextrose 5%+7.5% Inj G01016 19 Lignocaine 2% Gel G01014 20 Lignocaine 2,5% Gel G01033 21 Lignocaine 1% INJ G01034 22 Lignocaine 2% INJ G01015 23 Lignocaine 5% GEL G01035 24 Midazolam Injection 1 mg / ml Inj G01021 25 Midazolam Injection 5mg/ml Inj G01022 26 Nitrous Oxide Inhalation Inhalation G01006 27 Oxygen Inhalation Inhalation G01007 28 Propofol Injection 10 mg / ml Inj G01025 29 Sevoflurane 250MG Inhalation G01024 30 Thiopentone Injection I.P 0.5G 0.5G Inj G01008 31 Thiopentone Injection I.P 0.5G 1 G Inj G01009 32 Xylocaine spray 10% 10% Spray G01030 2. A n a l g e s i c s , A n t i p y r e t i c s , N o n s t e ro i d a l Anti-inflammatory Medicines, Medicines used to treat 33 AceclofenacRheumatoid 100mg Disorders.
    [Show full text]
  • New Zealand Data Sheet 1
    New Zealand Data Sheet 1. PRODUCT NAME Ibiamox® 250mg Powder for injection Ibiamox® 500mg Powder for injection Ibiamox® 1000mg Powder for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION The amoxicillin is present as the sodium salt in Ibiamox (1059mg of amoxicillin sodium is equivalent to approximately 1000mg of amoxicillin). Ibiamox 250mg Powder for injection contains 250mg amoxicillin. Ibiamox 500mg Powder for injection contains 500mg amoxicillin. Ibiamox 1000mg Powder for injection contains 1000mg amoxicillin. 3. PHARMACEUTICAL FORM Ibiamox vials: white to cream powder packed in clear glass vials for reconstitution. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications Amoxicillin should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. Amoxicillin is indicated for treatment of infections in adults and children at the following sites, when caused by sensitive organisms: • upper respiratory tract including ear, nose and throat infections, e.g. tonsillitis, sinusitis, otitis media • lower respiratory tract, e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia • gastrointestinal tract, e.g. typhoid fever • genito-urinary tract, e.g. cystitis, urethritis, pyelonephritis, bacteriuria in pregnancy, gonorrhoea, septic abortion, puerperal sepsis • other infections including Borreliosis (Borrelia burgdorferi) (Lyme Disease) • prophylaxis of endocarditis: amoxicillin may be used for the prevention of bacteraemia associated with the development of endocarditis (see table in section 4.2 Dose and method of administration) • Skin and soft tissue infections (SSSIs). Susceptibility to amoxicillin will vary with geography and time and local susceptibility data should be consulted where available and microbiological sampling and susceptibility testing performed where necessary (see section 5.1 Pharmacodynamic properties). 1 | Page 4.2.
    [Show full text]
  • Vocabulary of Medical Store(VMS) of Generic Drugs Sl VMS Code ITEM DESCRIPTION (NOMENCLATURE + STRENGTH + DOSAGE FORM + SPECIFICATION) PACK SIZE No
    Vocabulary of Medical Store(VMS) of Generic Drugs Sl VMS Code ITEM DESCRIPTION (NOMENCLATURE + STRENGTH + DOSAGE FORM + SPECIFICATION) PACK SIZE No. 1. ANAESTHETICS 1 G01019 ATROPINE INJECTION I.P 0.6 MG / ML 1 ML AMP 2 G01026 BENZOCAINE GEL 20% 15 GM TUBE 3 G01010 BUPIVACAINE INJECTION I.P 25MG/10ML 20 ML VIAL 4 G01011 BUPIVACAINE INJECTION I.P 50MG/10ML 20 ML VIAL 5 G01012 BUPIVACAINE IN DEXTROSE INJECTION 0.5% +7.5% 20 ML VIAL 6 G01027 DESFLURANE INHALATION 250ML BOTTLE 7 G01028 DEXMEDETOMIDINE INJECTION 100MG/ML 2 ML VIAL 8 G01020 DIAZEPAM INJECTION I.P 5 MG / ML 2 ML AMP 9 G01032 DOXAPRAM INJECTION 4 MG / ML 2 ML VIAL 10 G01013 ETHYL CHLORIDE SPRAY 1% 100ML CONTAINER 11 G01029 GLYCOPYRROOLATE INJECTION 0.2 MG/ML 1 ML AMP 12 G01002 HALOTHANE (WITH VAPORIZER) INHALATION 250ML BOTTLE 13 G01003 ISOFLURANE INHALATION 100ML BOTTLE 14 G01005 KETAMINE INJECTION I.P 50MG/ML 2 ML VIAL 15 G01004 KETAMINE INJECTION I.P 10 MG / ML 10 ML VIAL 16 G01017 LIGNOCAINE AND ADRENALINE INJECTION I.P 1% + 1:200,000 30 ML VIAL 17 G01018 LIGNOCAINE AND ADRENALINE INJECTION I.P 2% + 1:200,000 20 ML VIAL 18 G01016 LIGNOCAINE AND DEXTROSE INJECTION I.P 5% +7.5% 2 ML AMP 19 G01014 LIGNOCAINE GEL I.P 2% 30 GM TUBE 20 G01015 LIGNOCAINE INJECTION I.P 2% 30 ML VIAL 21 G01035 LIGNOCAINE GEL 5% 20GM TUBE 22 G01021 MIDAZOLAM INJECTION 1 MG / ML 5 ML VIAL 23 G01022 MIDAZOLAM INJECTION 5MG/ML 1 ML AMP 24 G01006 NITROUS OXIDE INHALATION 100 ML BOTTLE 25 G01007 OXYGEN INHALATION 100ML BOTTLE 26 G01025 PROPOFOL INJECTION I.P 10MG/ML 20 ML VIAL 27 G01024 SEVOFLURANE INHALATION 250 ML BOTTLE 28 G01008 THIOPENTONE INJECTION I.P 0.5G VIAL 29 G01009 THIOPENTONE INJECTION I.P 1G VIAL 30 G01030 XYLOCAINE SPRAY 10% 50 ML BOTTLE 2.
    [Show full text]
  • Unconjugated Estradiol, Estriol and Total Estriol in Maternal Peripheral
    Endocrinol. Japon. 1983, 30 (2), 155-162 Unconjugated Estradiol, Estriol and Total Estriol in Maternal Peripheral Vein, Cord Vein, and Cord Artery Serum at Delivery in Pregnancies with Intrauterine Growth Retardation. CHIKAYUKI, TAYAMA, SHUNZO ICHIMARU, MASAHARU ITO, MICHIO NAKAYANA, MASAO MAEYAMA AND ISAO MIYAKAWA Department of Obstetrics and Gynecology, Kumamoto University Medical School, Kumamoto 860 and *Department of Obstetricts and Gynecology, Miyazaki Medical College, Miyazaki Abstract The levels of unconjugated estradiol(E2), estriol (E3) and total (conjugated plus unconjugated) E3 in maternal vein serum during labor, cord vein serum, and cord artery serum were measured in normal singleton and twin pregnanceis with appropriate for dates babies (AFD) and with light for dates babies (LFD). The mean level of total E3 in the maternal vein serum in singleton pregnancy was significantlylower in the LFD group than in the AFD group, but no differenceswere seen in the mean levels of unconjugated E2 or E3 between the groups. The concentration of uncon- jugated E2 in the maternal vein serum was significantlyhigher in the twin group with a large placenta than in the singleton group with a small placenta, while the concentration of total E3 in the case of twin pregnancy with LFD was lower than that in singleton pregnancy with AFD but not significantly. No difference in the concentration of total E3 was observed between the cord vein serum and cord artery serum. The present data suggest that the total E3 level in maternal vein serum may be used in evaluating fetal states such as intrauterinegrowth retardation. In pregnancy complicated by intrauterine conjugated E2 and E3 into the maternal and growth retardationwith or without symptoms fetal circulation and to determine the total of maternal disease,such as toxemia of pre- (conjugated plus unconjugated) E3 in the gnancy or hypertension,not only the urinary maternal and fetal blood.
    [Show full text]
  • Thesis.Pdf (432.0Kb)
    Some hormonal factors in the etiology of endometrial cancer Elisabete Weiderpass Stockholm 1999 Department of Medical Epidemiology, Karolinska Institutet, Stockholm, Sweden Some hormonal factors in the etiology of endometrial cancer Elisabete Weiderpass Stockholm 1999 2 To all women who took part in these studies 3 ABSTRACT The main purpose of this dissertation was to study the impact of some hormone-related factors in the etiology of endometrial neoplasms, i.e. hormone replacement therapy, use of oral contraceptives, serum levels of 20 different organochlorine substances, and polymorphisms in the estrogen receptor α (ER) gene. We conducted two population-based case-control studies among post-menopausal women. In the first one, 789 women with a reported diagnosis of primary endometrial cancer and 3368 age-frequency-matched control women were enrolled from all over Sweden. These women answered a questionnaire on use of oral contraceptives and hormone replacement therapy, among other questions. We used unconditional logistic regression to calculate odds ratios (OR) as estimates of relative risks. We found a duration-dependent increase in the relative risk of endometrial cancer both among women who used orally administered estriol, 1-2 mg/day (multivariate OR following 5 or more years of use: 3.0; 95% confidence interval [CI] 2.0-4.4) and medium-potency estrogens without addition of progestins (multivariate odds ratio following 5 or more years of use: 6.7; 95% CI 4.3-10.5), compared to women who never used these substances. Following combined estrogen-progestin use, the association was considerably weaker (multivariate odds ratio following 5 or more years of use: 1.6; 95% CI 1.1-2.4) than for estrogens without progestins, and the increased relative risk was confined to women using cyclic regimens (i.e.
    [Show full text]
  • Department of Health & Human Services Nda 50-757/S
    Public Health Service DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Rockville, MD 20857 NDA 50-757/S-011 PRIOR APPROVAL SUPPLEMENT TAP Pharmaceutical Products Inc. Attention: John R. Lieberman, Ph.D Regulatory Advisor 675 North Field Drive Lake Forest, IL 60045 Dear Dr. Lieberman: Please refer to your supplemental new drug application dated January 31, 2005, received February 1, 2005, submitted under section 505(b)(1) of the Federal Food, Drug and Cosmetic Act for PREVPAC® (lansoprazole/amoxicillin/clarithromycin). This supplemental new drug application provides for the following revisions to the package insert (additions are double underlined and deletions are strikethrough): 1. The TRIMOX® (amoxicillin, USP) subsection of the DESCRIPTION section was revised to read: Amoxicillin, USP, (2S,5R,6R)-6-[( R)-(-)-2-Amino-2-(p-hydroxyphenyl) acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate is a semi-synthetic penicillin antibiotic, an analogue of ampicillin, with a broad spectrum of bactericidal activity against many gram –positive and gram-negative microorganisms. Chemically it is (2S,5R,6R)-6-[( R)-(-)-2-Amino- 2-(p-hydroxyphenyl) acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0] heptane-2-carboxylic acid trihydrate. Amoxicllin capsules are intended for oral administration. 2. The Amoxicillin: subsection of the CLINICAL PHARMACOLOGY section was revised to read: Most of the amoxicillin is excreted unchanged in the urine; its excretion can be delayed by concurrent administration of probenicid. Amoxicillin is not highly protein bound. In blood serum, amoxicillin is approximately 20% protein bound as compared to 60% for penicillin G.
    [Show full text]
  • Study Protocol Drug Substance Ceftazidime-Avibactam Study Code D4280C00015 Edition Number 2 Date 07 March 2017 Approximately 70 Study Centres Are Planned
    .9/L"H(A"L .-4*.LDF KL09E:92L Qe2ne"V`J'+n ')PX-$-9'T/Z!J:Z ^f)kn L),n Z *6Z7LIneE",Pn Z [,n ZC!+Z Z @4 +'@ ( ,@ +.) 4@)8'5!+51@ 6 :@ .,51.''@52 '@6.@; '9 5@ 4 5=@ 5.'7 ' 6=@/ ) .& +6!4@ +@" =@.@5 > *@ +@ ; 5 )@<-@ #;,@ #,@.) + 5 .,@< 5@)51.+! ?.(@ .)0 2@< 5@ 32./+)@ +@ (1,@2.)@ ).+64@6.@'44@5 +@ = 24@ .@ @<$6@ .)0( 6@ ,6 .)!, '@ +5!.+4@% %4@ <97A9=L V`P'I&' n bD),P[;?<,ni,*,In PPD AE="5"L"B">%L5L )!# B(E"L >";?"B"6DE+I"L PPD \,n \f*ln-).Pn PP n D n n PP n,Z4,P?!I)Wn PPD n n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e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT) PROTOCOL SYNOPSIS A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam when given in combination with metronidazole, compared with meropenem, in children from 3 months to less than 18 years of age with complicated intra-abdominal infections (cIAIs) International Co-ordinating Investigator PPD , MD PPD United States Study site(s) and number of patients planned A sufficient number of patients are to be randomised 3:1 for 80 patients to complete at least 72 hours (3 full days, ie, 9 doses) of study treatment (ie, evaluable patients; at least 60 patients in the ceftazidime and avibactam [CAZ-AVI] plus metronidazole group and at least 20 patients in the meropenem group).
    [Show full text]
  • UNASYN® (Ampicillin Sodium/Sulbactam Sodium)
    UNASYN® (ampicillin sodium/sulbactam sodium) To reduce the development of drug-resistant bacteria and maintain the effectiveness of UNASYN® and other antibacterial drugs, UNASYN should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION UNASYN is an injectable antibacterial combination consisting of the semisynthetic antibacterial ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium for intravenous and intramuscular administration. Ampicillin sodium is derived from the penicillin nucleus, 6-aminopenicillanic acid. Chemically, it is monosodium (2S, 5R, 6R)-6-[(R)-2-amino-2-phenylacetamido]-3, 3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0] heptane-2-carboxylate and has a molecular weight of 371.39. Its chemical formula is C16H18N3NaO4S. The structural formula is: COONa O CH 3 N CH O 3 NH S NH 2 1 Reference ID: 4683820 Sulbactam sodium is a derivative of the basic penicillin nucleus. Chemically, sulbactam sodium is sodium penicillinate sulfone; sodium (2S, 5R)-3,3-dimethyl-7-oxo-4-thia- 1-azabicyclo [3.2.0] heptane-2-carboxylate 4,4-dioxide. Its chemical formula is C8H10NNaO5S with a molecular weight of 255.22. The structural formula is: COONa CH 3 O N CH 3 S O O UNASYN, ampicillin sodium/sulbactam sodium parenteral combination, is available as a white to off-white dry powder for reconstitution. UNASYN dry powder is freely soluble in aqueous diluents to yield pale yellow to yellow solutions containing ampicillin sodium and sulbactam sodium equivalent to 250 mg ampicillin per mL and 125 mg sulbactam per mL. The pH of the solutions is between 8.0 and 10.0.
    [Show full text]